Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NV-387 oral adaptive phase 2 study in Ebola virus disease
PACTR202608748555077Phase 2Not yet recruiting
- Start
- Aug 2026
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2 trial of NV-387 in Ebola virus disease (EVD). Planned start Aug 2026; status: not yet recruiting.
02
Drugs
NV-387
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on PACTR202608748555077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202608748555077.